CLSP-5282

CLSP-5282 is a first-in-class T cell engager (TCE) designed to selectively target the KRas G12V mutant peptide (specifically the 7-16 fragment) presented on the HLA-A*03:01 major histocompatibility complex. Developed by Cullinan Therapeutics, the molecule is engineered to bridge T cells with tumor cells expressing the specific neoantigen-HLA complex, leading to T cell activation and directed cytotoxicity. Unlike small molecule KRas inhibitors that bind the protein directly, CLSP-5282 targets the peptide-HLA complex on the cell surface, potentially overcoming resistance mechanisms associated with direct Ras inhibition. Preclinical studies have demonstrated potent anti-tumor activity in humanized mouse models and high specificity, with no cross-reactivity to wild-type KRas or other common HLA alleles.